193 related articles for article (PubMed ID: 37827154)
21. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
23. Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantation.
Atta EH; de Oliveira DC; Bouzas LF; Nucci M; Abdelhay E
PLoS One; 2014; 9(9):e107155. PubMed ID: 25188326
[TBL] [Abstract][Full Text] [Related]
24. Graft versus leukaemia effects after marrow transplantation in man.
Brenner MK; Heslop HE
Baillieres Clin Haematol; 1991 Jul; 4(3):727-49. PubMed ID: 1958889
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.
Li JM; Petersen CT; Li JX; Panjwani R; Chandra DJ; Giver CR; Blazar BR; Waller EK
Cancer Res; 2016 Dec; 76(23):6802-6815. PubMed ID: 27671676
[TBL] [Abstract][Full Text] [Related]
26. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
27. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
28. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
29. The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment.
Sosman JA; Sondel PM
Am J Pediatr Hematol Oncol; 1993 May; 15(2):185-95. PubMed ID: 8498642
[TBL] [Abstract][Full Text] [Related]
30. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
31. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model.
Burlion A; Brunel S; Petit NY; Olive D; Marodon G
Front Immunol; 2017; 8():756. PubMed ID: 28713380
[TBL] [Abstract][Full Text] [Related]
33. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
[TBL] [Abstract][Full Text] [Related]
34. Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity.
Slavin S; Moss RW; Bakacs T
Pharmacol Res; 2014 Jan; 79():9-12. PubMed ID: 24200897
[TBL] [Abstract][Full Text] [Related]
35. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
Prigozhina TB; Gurevitch O; Morecki S; Yakovlev E; Elkin G; Slavin S
Exp Hematol; 2002 Jan; 30(1):89-96. PubMed ID: 11823042
[TBL] [Abstract][Full Text] [Related]
36. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
37. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
38. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
39. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]